CA
ABOS icon

Clearstead Advisors’s Acumen Pharmaceuticals ABOS Stock Holding History

Clearstead Advisors’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$142 Hold
60
– – ﹤0.01% 2187
2025
Q4 		$127 Buy
+60
New +$119 ﹤0.01% 2479
2025
Q3 		– Sell
-63
Closed -$74 – 3087
2025
Q2 		$74 Buy
+63
New +$68 ﹤0.01% 2644

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $992M AUM 28.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Clearstead Advisors's ABOS Position: Q1 2026 in Review

Clearstead Advisors held its Acumen Pharmaceuticals (ABOS) position steady in Q1 2026 at 60 shares worth $142. The position accounts for ﹤0.01% of the portfolio, ranked #2187.

Clearstead Advisors first reported a position in ABOS in Q2 2025 and has held it in 3 quarters since. 84 funds tracked by Wall St. Rank hold ABOS as of Q1 2026.

  • Clearstead Advisors held 60 shares of Acumen Pharmaceuticals worth $142 as of Q1 2026.
  • Clearstead Advisors left its Acumen Pharmaceuticals share count unchanged in Q1 2026.
  • Acumen Pharmaceuticals made up ﹤0.01% of Clearstead Advisors's portfolio in Q1 2026, its #2187 holding.
  • Clearstead Advisors first reported a position in Acumen Pharmaceuticals in Q2 2025 and has held it in 3 quarters since.
  • 84 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q1 2026.

Based on Clearstead Advisors's 13F filing for Q1 2026, filed 6 May 2026.